HVH and Patient iP Team Up to Improve Clinical Trials

By | News | No Comments

February 13, 2018 — King of Prussia, PA — HVH Precision Analytics, a predictive analytics company accelerating the effective use of machine learning on the real-world data landscape to help healthcare organizations attain actionable results, and Patient iP, a health data and analytics company providing patient data insights to accelerate and transform clinical research, are partnering to improve clinical trial design, site selection and patient enrollment.

The companies will collaborate using HVH’s proprietary SCIPHER machine learning platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment. HVH combines data and therapeutic area agnostic analytic and medical capabilities, and Patient iP’s platform contains data from more than 4,000 practice sites and 16 million ambulatory electronic medical records (EMR). The combination will bring powerful changes to clinical trials.

“Coupling HVH’s unique machine learning capabilities broadly applied to real-world data and Patient iP’s significant EMR and site access will significantly improve our companies’ ability to assist CROs and clinical trial sponsors with site selection and targeting, leading to improved trial enrollment,” said Steve Costalas, CEO of HVH.

“Patient iP is excited to partner with HVH given their rich heritage of predictive analytics and innovation. By integrating their significant data science capabilities with our robust identifiable patient database and deep clinical trial expertise, we offer a new data-driven approach to solving the patient recruitment challenges in clinical research,” said Mike Wilkinson, President and COO of Patient iP.

About HVH
HVH is a proven provider of predictive analytics solutions. HVH is shortening the time to diagnosis through the application of a proven and validated methodology to real-world data to find diagnosed patients, prospective therapy candidates, undiagnosed patients and ideal candidates for clinical trials so that innovative therapies find the patients who desperately need them. For more information about HVH, visit www.hvhprecision.com.

About Patient iP
The patented Patient iP data analytics platform provides unique value for the clinical research industry. Using a cloud-based infrastructure, the company leverages aggregated patient data to streamline and accelerate clinical trial design, site selection and participant matching to bring new therapies to market faster and more cost effectively. Deployed in concert, Patient iP’s award-winning technology and expansive daTAscape enhance recruitment efforts, increase performance predictability, and maximize research yield given a focus on the untapped community-based patient market. For more information, visit us at www.patientip.com or follow us on Twitter @PatientIP.

CRO Industry Veteran Mike Wilkinson Joins Patient iP as President and COO

By | News | No Comments

January 11, 2018 – Rochester, NY – Patient iP, a health data and analytics company providing patient data insights to accelerate and transform clinical research, today announced that Mike Wilkinson has been named company President and Chief Operating Officer effective immediately.  He will report directly to Chairman, Founder and Chief Executive Officer, Michael Margiotta.

Wilkinson joins Patient iP with more than nineteen years in the pharmaceutical industry, the last 15 of those in executive leadership positions.  He spent the past ten years at PPD, a leading global contract research organization (CRO) providing comprehensive, integrated drug development, laboratory and lifecycle management services. At PPD Wilkinson first served as Executive Vice President (EVP) and Global Head of Clinical Development.  Most recently he served as EVP and Chief Information Officer (CIO) where he led PPD’s global technology, innovation and performance group. Prior to PPD, Wilkinson held numerous positions at Quintiles, another leading global CRO, with his last role being Global Head of Internal Medicine.

Read More

Leveraging Patient Health Data to Drive Clinical Trial Feasibility and Recruitment Improvements

By | News | No Comments

Though the adoption curve of technology within the clinical research space is expanding, paper-based and manual processes still play a major role in the execution of trials. Fortunately for all stakeholders, this is all about to change thanks to progressive medical practitioners that now understand the value of the clinical data they have collected: the massive digital repositories that for many years were viewed as administrative in nature and overlooked for the applicability to accelerate clinical research. Take a look at what Patient iP CIO Ann Dokus has to say on this matter.

Click here to read the article

Outsourcing Pharma: Patient iP’s clinical trial matching solution tops 14m patient records

By | News | No Comments

Patient identification Platform (Patient iP) has been growing its Connected Site Network over the past two years – as it aims to curate one of the largest patient-centric, longitudinal clinical data sets in the world, says CEO.

Patient iP is a health data network supplier to the pharmaceutical and contract research organization (CRO) industries. Its Connected Site Network has more than 14m unique patient records across 4,000 practice sites.

According to the company, the solution improves the clinical trial site selection process as well as patient matching for clinical trial participation.

Read more: http://www.outsourcing-pharma.com/Clinical-Development/Patient-iP-s-clinical-trial-matching-solution-tops-14m-patient-records

Patient identification Platform and Aprima Announce Strategic Partnership to Improve Clinical Trial Recruitment Efforts

By | News, Uncategorized | No Comments

Rochester, NY – July 25, 2017 – Patient identification Platform (Patient iP), an emerging health data solutions provider to the pharmaceutical and CRO industries, today announced a new partnership with Aprima® Medical Software. Aprima is a leading provider of innovative electronic health records (EHR), practice management and revenue cycle management solutions for medical practices. This collaboration enables the integration of Aprima EHR data and Patient iP’s clinical trial matching solution. Read More

Patient identification Platform Data Network Surpasses 14 Million Unique Patients Lives, Achieving Significant Growth Milestone

By | News | No Comments

Rochester, NY – July 11, 2017 – Patient identification Platform (Patient iP), an emerging health data network supplier to the pharmaceutical and CRO industries, today announced that the company’s Connected Site Network now represents more than 14 million unique patient records across 4,000 practice sites. This achievement comes only two years after the launch of the Platform for objective clinical trial matching, a solution hailed by Microsoft in 2016 as a Health Innovation Award winner. Read More

Disrupting Traditional Patient Recruitment Via Identification Analytics

By | News | No Comments

Over 80 percent of clinical trials today fail to meet their stated timelines. Low recruitment/patient enrollment and retention from under-performing sites stalls clinical trials and is costly on a variety of levels. Despite vast and varied efforts, this has not changed greatly over the past two decades. Considering the advances that have been made in many other areas of research with process improvement and technology, e.g. electronic data capture, risk-based monitoring and sophisticated visual analytics, the advances in patient recruitment have not kept pace or yielded the desired benefits. Read More

Innovations in Patient Matching – Applied Clinical Trials

By | News | No Comments

Two years ago, Applied Clinical Trials looked at the technologies intending to close the ever-elusive patient recruitment gap. In that time, other innovative approaches have emerged, and while there are no hard and fast numbers that any have in fact sped up the recruitment process, many have re-imagined electonic health records (EHRs), and offer insight into the future of personalized medicine, as well as the physician’s role in clinical trials.

Read the whole story here